A Virtual Reality View: New Approaches to the Diagnosis and Treatment of Pediatric and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis

 
Date Time City Location Registration Link
03-15-20 6:45-8:00AM Philadelphia AAAAI Annual Meeting
Philadelphia Marriott Downtown
1201 Market Street
Philadelphia, PA 19107
Meeting room: Level 5, Grand Ballroom Salon H

REGISTER NOW
03-20-20 6:30-8:00 PM Denver, CO AAD 78th Annual Meeting
Sheraton Denver Downtown Hotel
1550 Court Place
Denver, CO 80202
Meeting room: Majestic Ballroom

REGISTER NOW

 

PROGRAM FEATURES

  • Virtual reality headsets provided to attendees for viewing this presentation only
  • iPads provided to enhance learning experience
  • Create your own personalized poster
  • Interactive, case-based learning environment

PROGRAM DESCRIPTION

While guidelines regarding the management of AD in children have been published, variability persists in practice. Treatment inconsistencies and the chronic and relapsing nature of AD can lead to frustration for patients, family, and caregivers when managing AD. This program will focus on providing AD caregivers an update on recent pathophysiological findings that drive new therapeutic targets; reviewing severity and diagnosis of AD; and discussing the clinical profiles of existing and emerging agents, with focus on treatment individualization.

LEARNING OBJECTIVES

  • Apply updated diagnostic guidance for pediatric and adolescent patients with moderate-to-severe AD and use severity assessments to inform management decisions
  • Review the clinical profiles and mechanisms of action of newly approved and emerging systemic/biologic agents for the treatment of pediatric and adolescent patients with moderate-to-severe AD
  • Explain the benefits associated with patient centered, team-based shared decision-making approaches for the management of moderate-to-severe AD in children and adolescents

TARGET AUDIENCE

This activity is intended for US-based pediatric/adolescent dermatologists, allergists/immunologists and other health care professionals who diagnose and manage pediatric/adolescent patients with moderate-to-severe AD.

DISCLAIMER

Med Learning Group makes every effort to develop activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For questions, please contact Med Learning Group at info@medlearninggroup.com.
Privacy and confidentiality policy statement information is available at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event Staff will be glad to assist you with any special needs (i.e. physical, dietary, etc.) Please contact Med Learning Group prior to the live event at info@medlearninggroup.com

 

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.